semaglutide novo nordisk patent Ozempic just got much, much cheaper in India. On March 21, Danish company Nordisk's on semaglutide, the active ingredient behind its diabetes and weight-loss drugs Ozempic and Wegovy, expired in Novo Nordisk does not expect

Regional Insights North America GLP-1 Receptor Agonist Market Insights North America dominated the global GLP-1 Receptor Agonist Market in 2025 with approximately 45% of global revenues, anchored entirely by the United States' unique drug pricing environment and the commercial investment that Novo Nordisk and Eli Lilly have made in building GLP-1 prescribing across endocrinology, primary care, cardiology, and bariatric medicine

This results in gradually decreasing inputs of low 34 S into the plant available sulfate pool from sulfide reserves near the soil surface

The most common comorbidity is psoriatic arthritis, which occurs in about a third of patients

Purity and endotoxin certificates are linked at the product level when a corresponding PDF exists for the batch